PREVALENCE OF ANTI-SARS-COV-2 IGG ANTIBODIES IN SKOPJE, NORTH MACEDONIA: TWO-TIME POINTS POPULATION-BASED CROSS-SECTIONAL STUDY

Authors

  • Kristina Stamatovska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Meri Kirijas Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Marija Gnjatović University of Belgrade, Institute for the Application of Nuclear Energy INEP, 11000 Belgrade, Serbia
  • Danica Ćujić University of Belgrade, Institute for the Application of Nuclear Energy INEP, 11000 Belgrade, Serbia
  • Dejan Trajkov Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Elena Cvetkovska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Sanja Kajevikj Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Dragica Bliznakovska Stanchev Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Vangel Ristovski Institute of Medical Physiology and Anthropology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Olgica Sibinovska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Tamara Savevska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Stefani Iljoska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Boban Dobrevski Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Olivija Efinska Mladenovska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Gorjan Milanovski Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Todor Arsov Faculty of Medical Sciencies, University Goce Delchev in Shtip, Shtip, North Macedonia
  • Teodora Brnjarchevska Blazhevska Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia
  • Aleksandar Petlichkovski Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia

Keywords:

COVID-19, seroprevalence, anti-SARS-CoV-2 antibodies, population study

Abstract

The aim of our study was to determine the seroprevalence of IgG anti-SARS-CoV-2 antibodies in Skopje, the capital of North Macedonia at two time points, February 2021, and February 2022 and to provide information about the dynamics of the collective immunity.

We recruited a total of 1004 in the first and 971 random individuals in the second time point who answered a questionnaire and IgG anti-SARS-CoV-2 antibodies against S and N antigen were measured.

The estimated overall seroprevalence in Skopje in February 2021 was 31.4%, with no statistical difference between different age groups or gender. Positive RT-PCR test or presence of symptoms associated with COVID-19 strongly correlated with presence of anti-SARS-CoV-2 antibodies (p<0.001). At the second time point the overall seroprevalence was 86.8%, somewhat higher in the group of participants vaccinated against COVID-19 with one of the six different vaccines compared to the unvaccinated group (89.9% vs. 75.8%, p<0.001). In the subgroup of individuals without prior positive RT-PCR test and unvaccinated, 69 out of 105 (65.7%) had IgG anti-SARS-CoV-2 antibodies.

Estimation of population seroprevalence is valuable information that reflect the immunization status of the population in the capitol of North Macedonia. However, the emergence of different subvariants of Omicron challenges the importance of collective immunity in prevention of new infection.

References

Dashboard C. Center for Systems Science and Engineering at Johns Hopkins University. Available at: https://coronavirus.jhu.edu/map.html. Accessed 11th April 2022

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; May: 20 (5): 533–4.

Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic testing for severe acute respiratory syndrome–related coronavirus 2: A narrative review. Ann Intern Med 2020; 172 (11): 726-734. doi: 10.7326/M20-1301.

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance 2020; 25 (10): 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.

Plebani M, Padoan A, Fedeli U, Schievano E, Vecchiato E, Lippi G, et al. SARS-CoV-2 serosurvey in health care workers of the Veneto Region. Clin Chem Lab Med 2020; 58 (12): 2107-2111. doi: 10.1515/cclm-2020-1236.

Department of Health, N. M. 2021. p. https://koronavirus.gov.mk. Accessed 11th April 2022.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021; 5 (7): 947-953. doi: 10.1038/s41562-021-01122-8.

Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, et al. Seroepidemiologic study designs for determining SARS-COV-2 transmission and immunity. Emerg Infect Dis 2020; 26 (9): 1978-1986. doi: 10.3201/eid2609.201840.

WHO. A coordinated global research roadmap: 2019 novel coronavirus. 2020. Accessed 11th April 2022

WHO. Global surveillance for COVID-19 disease caused by human infection with the 2019 novel coronavirus. Available from: https://www.who.int/publications-detail/global-sur. Accessed 11th April 2022

WHO. Population-based age stratified seroepidemiological investigation protocol for COVID-19 virus infection Available from: https://apps.who.int/iris/handle/10665/331656. Accessed 11th April 2022

Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature 2021; 590 (7844): 146-150. doi: 10.1038/s41586-020-2912-6.

Santarelli A, Lalitsasivimol D, Bartholomew N, Reid S, Reid J, Lyon C, et al. The seroprevalence of sars-cov-2 in a rural southwest community. J Osteopath Med 2021; 121 (2): 199-210. doi: 10.1515/jom-2020-0287.

Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. J Infect 2020; 81 (6): 931-936. doi: 10.1016/j.jinf.2020.10.011.

Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis 2021; 21 (4): 473-481. doi: 10.1016/S1473-3099(20)30858-6.

Prakash O, Solanki B, Sheth JK, Joshi B, Kadam M, Vyas S, et al. Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: A cross-sectional study. BMJ Open 2021; 11 (1): e044101. http://dx.doi.org/10.1136/bmjopen-2020-044101.

Stefanelli P, Bella A, Fedele G, Pancheri S, Leone P, Vacca P, et al. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Clin Microbiol Infect 2021; 27 (4): 633.e1-633.e7. doi: 10.1016/j.cmi.2020.11.013.

Del Brutto OH, Costa AF, Mera RM, Recalde BY, Bustos JA, García HH. SARS-CoV-2 in Rural Latin America. A Population-based Study in Coastal Ecuador. Clin Infect Dis 2021; 73 (2): 314-317. doi: 10.1093/cid/ciaa1055.

Census of the population of Republic of North Macedonia. Available from: https://popis2021.stat.gov.mk/. Accessed 11th April 2022.

Prguda-Mujic J, Hasanic O, Besic L, Asic A, Halilovic S, Cesic AK, et al. Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina—One year later. Nasrallah GK, editor. PLoS One 2022; 17 (3): e0265431. doi: 10.1371/journal.pone.0265431. eCollection 2022.

Rares Olariu T, Cristiana Craciun A, Cristina Vlad D, Dumitrascu V, Laurentiu Pop L, Horhat F, et al. SARS-CoV-2 Seroprevalence in Children from Western Romania. Vector Borne Zoonotic Dis 2022; 22 (4): 267–270. doi: 10.1089/vbz.2022.0003.

Hønge BL, Hindhede L, Kaspersen KA, Harritshøj LH, Mikkelsen S, Holm DK, et al. Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection. Int J Infect Dis 2022;116: 289–292. doi: 10.1016/j.ijid.2022.01.041.

Murad D, Chandrasekaran S, Pillai A, Garner OB, Denny CT. Sars-cov-2 infection detection by pcr and serologic testing in clinical practice. J Clin Microbiol 2021; 59 (7): e0043121. doi: 10.1128/JCM.00431-21.

Report from the Institute of Public Health of Republic of North Macedonia Available from: https://www.iph.mk/. Accessed 6th March 2022.

Pollán M, Pérez-gómez B, Pastor-barriuso R, Oteo J, Hernán MA, Pérez-olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396 (10250): 535–544. doi: 10.1016/S0140-6736(20)31483-5.

Anne G, Legrand K, Jay N, Bochnakian A, Vallois P, Schvoerer E, et al. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France. Viruses 2021; 13 (6): 1076. doi: 10.3390/v13061076.

Gashi B, Osmani V, Halili R, Hoxha T, Kamberi A, Hoti N, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies among Municipal Staff in the Municipality of Prishtina. Int J Environ Res Public Heal 2021; 18 (23): 12545. doi: 10.3390/ijerph182312545.

Metcalf C, Farrar J, Cutts F, Basta N, Graham A, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet 2016; 388 (10045): 728–30. doi: 10.1016/S0140-6736(16)30164-7.

Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. J Assoc Med Microbiol Infect Dis Can 2020; 5 (4): 223–234. doi: 10.3138/jammi-2020-0030. eCollection 2020 Dec.

Permatasari S. Almost All Indonesians Have Covid Antibody, March Survey Shows. Available from: https://www.bloomberg.com/news/articles/2022-04-18/almost-all-indonesians-have-covid-antibody-march-survey-shows. Accessed 11th April 2022

Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/ healthand socialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/antibodies. Accessed 11th April 2022

Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, et al. Pfizer-biontech and sinopharm: A comparative study on post-vaccination antibody titers. Vaccines (Basel) 2021; 9 (11): 1223. doi: 10.3390/vaccines9111223.

Brnjarchevska Blazhevska T, Babačić H, Sibinovska O, Dobrevski B, Kirijas M, Milanovski G, et al. A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals. Allergy 2022; 77 (1): 296–298. doi: 10.1111/all.15047.

Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I, et al. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Med 2021; 2 (8): 100359. doi: 10.1016/j.xcrm.2021.100359.

Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S, et al. Neutralizing antibodies in covid-19 patients and vaccine recipients after two doses of BNT162b2. Viruses 2021; 13 (7): 1364. doi: 10.3390/v13071364.

Mueller T. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer. Clin Chim Acta 2021; 518: 9–16. doi: 10.1016/j.cca.2021.03.007.

Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol 2021; 93 (9): 5560–5567. doi: 10.1002/jmv.27098.

Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, et al. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis. Am J Kidney Dis 2022; 79 (2): 185-192.e1. doi: 10.1053/j.ajkd.2021.08.005.

Sanchez L, Oviedo Rouco S, Pifano M, Ojeda D, Pascuale C, Mazzitelli B, et al. Antibody durability at 1 year after Sputnik V vaccination. Lancet Infect Dis 2022; 22 (5): 589–90. doi: 10.1016/S1473-3099(22)00176-1.

Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Glob Heal 2021; 9 (7): e925-e931. doi: 10.1016/S2214-109X(21)00173-X.

Downloads

Published

2023-06-16 — Updated on 2023-07-06

Versions

Issue

Vol. 3 No. 2 (2023): Acad Med J

Section

Original Articles